Skip to main content

Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software

AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies    RADNOR, PA – June 17, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today unveiled its next-generation CoAuthor regulatory writing software.  CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, … Continued

Certara Appoints New Chief Human Resources Officer & General Counsel

RADNOR, PA – May 21, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.  Rona Anhalt Chief Human Resources Officer Daniel CorcoranGeneral Counsel “Rona and Daniel are leaders in their fields. They have proven track records … Continued

Certara Reports First Quarter 2024 Financial Result

Reiterates Full Year 2024 Financial Guidance PRINCETON, N.J.— May 7, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024. First Quarter Highlights: “I am pleased with our first quarter financial results, steered by solid execution across both software and services,” said William … Continued

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

PRINCETON, NJ – April 16, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to … Continued

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

PRINCETON, N.J.— April 9, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening … Continued

Certara Reports Fourth Quarter 2023 Financial Results

Provides Full Year 2024 Financial Guidance PRINCETON, N.J.— February 29, 2024– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023. Fourth Quarter Highlights: “We are encouraged by our strong fourth quarter results, driven by improved execution across both software and services,” said William … Continued

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at … Continued

Certara Acquires Applied Biomath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Combined organization establishes the life Sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. Princeton, NJ – December 14th, 2023   – Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied Biomath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and … Continued

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development 

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies Princeton, NJ – November 21st, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed for use by biopharmaceutic, formulation, and CMC scientists to aid in formulating complex … Continued

1 of 33